-- Alan Mozes
WEDNESDAY, Jan. 2 (HealthDay News) -- Women who take certain
antidepressants while pregnant do not raise the risk of a
stillbirth or death of their baby in the first year of life,
according to a large new study.
The findings stem from an analysis involving 30,000 women in
Denmark, Finland, Iceland, Norway and Sweden, who gave birth to
more than 1.6 million babies, in total, between 1996 and 2007.
Close to 2 percent of the women took prescription selective
serotonin reuptake inhibitors (SSRIs), such as Prozac (fluoxetine)
and Paxil (paroxetine), for depressive symptoms during their
The research team, led by Dr. Olof Stephansson of the Karolinska
Institute in Stockholm, Sweden, reports in the Jan. 2 issue of the
Journal of the American Medical Associationthat initially
women taking an SSRI for depression did seem to experience
statistically higher rates of stillbirth and infant death. However,
that uptick in risk disappeared once they accounted for other
factors, including the threat posed by depression and the mother's
history of psychiatric disease or hospitalizations, the authors
noted in a journal news release.
"The present study of more than 1.6 million births suggests that SSRI use during pregnancy was not associated with increased risks of stillbirth, neonatal death or postneonatal death," Stephansson's team reported.
"The increased rates of stillbirth and postneonatal mortality among infants exposed to an SSRI during pregnancy were explained by the severity of the underlying maternal psychiatric disease and unfavorable distribution of maternal characteristics such as cigarette smoking and advanced maternal age," the authors added.
Depression during pregnancy affects between 7 percent and 19
percent of mothers-to-be in economically developed countries, the
authors pointed out in the report. "Maternal depression is
associated with poorer pregnancy outcomes, including increased risk
of preterm delivery, which in turn may cause neonatal morbidity and
mortality," they explained.
The team acknowledged that use of SSRIs during pregnancy has
been associated with birth defects, neonatal withdrawal syndrome
and pulmonary hypertension of the newborn, which is what led to the
current study, they said.
Although they found that the drugs posed no independent risk
regarding stillbirth or infant death, the authors urged mothers and
physicians to approach SSRI use carefully.
"Decisions regarding use of SSRIs during pregnancy must take into account other perinatal outcomes and the risks associated with maternal mental illness," Stephansson and colleagues concluded.
For more on antidepressants, visit the
U.S. National Library of Medicine.
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.